Jermaine D. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jermaine D. Jones has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Sandra D. Comer
Department of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center
20 shared publicationsSuky Martinez
Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine
10 shared publicationsJeanne M. Manubay
Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, USA
7 shared publicationsShanthi Mogali
Division on Substance Use Disorders, Department of Psychiatry, New York State Psychiatric Institute, and Columbia University Irving Medical Center
6 shared publicationsVerena E. Metz
Kaiser Permanente Division of Research, Center for Addiction and Mental Health Research, 2000 Broadway, Oakland, CA 94612, USA
6 shared publicationsGabriela Madera
Division on Substance Use Disorders, Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, USA
5 shared publications
Latest Publications
- 1 June 2026
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 34 (3) , 318-323
The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.
Naloxone administration can precipitate opioid withdrawal, concerns about which may result in hesitancy to use this life-saving intervention. Preclinical and clinical research suggests that cannabinoids may reduce the symptoms associated with opioid withdrawal. This proof-of-concept study sought to test the effects of vaporized cannabis pretreatment (T-15 min) on naloxone-precipitated (T0-T+50) withdrawal using the Clinical Opiate Withdrawal Scale (COWS, range = 0-48) as the primary dependent measure. Evaluating the safety of this drug combination was the secondary aim, assessed using vital signs. Before a major methodological redesign, a single participant (male, 52) with opioid use disorder completed testing. The ∼4-week inpatient study began with stabilization on oral morphine (120 mg/day). During testing, the following dose combinations of vaped cannabis (V-CB) and intranasal naloxone (IN-NLX) were tested: (a) IN-NLX 0.0 mg + V-CB 25.0 mg, (b) IN-NLX 4.0 mg + V-CB 0.0 mg, (c) IN-NLX 0.0 mg + V-CB 12.5 mg, (d) IN-NLX 4.0 mg + V-CB 12.5 mg, (e) IN-NLX 0.0 mg + V-CB 0.0 mg, and (f) IN-NLX 4.0 mg + V-CB 25.0 mg. Naloxone alone resulted in a COWS score of 22 at T+30. CB pretreatment (12.5 mg and 25.0 mg) reduced COWS scores at T+30 to 17 and 14, respectively. Active NLX and V-CB administered in combination resulted in elevated heart rate and blood pressure, though not to a greater extent than NLX alone. This study found that the addition of a cannabinoid reduced the severity of NLX-precipitated withdrawal and supported the continued investigation into combined NLX + cannabinoid formulations as overdose reversal agents. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- 1 June 2026
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 34 (3) , 318-323
The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.
Naloxone administration can precipitate opioid withdrawal, concerns about which may result in hesitancy to use this life-saving intervention. Preclinical and clinical research suggests that cannabinoids may reduce the symptoms associated with opioid withdrawal. This proof-of-concept study sought to test the effects of vaporized cannabis pretreatment (T-15 min) on naloxone-precipitated (T0-T+50) withdrawal using the Clinical Opiate Withdrawal Scale (COWS, range = 0-48) as the primary dependent measure. Evaluating the safety of this drug combination was the secondary aim, assessed using vital signs. Before a major methodological redesign, a single participant (male, 52) with opioid use disorder completed testing. The ∼4-week inpatient study began with stabilization on oral morphine (120 mg/day). During testing, the following dose combinations of vaped cannabis (V-CB) and intranasal naloxone (IN-NLX) were tested: (a) IN-NLX 0.0 mg + V-CB 25.0 mg, (b) IN-NLX 4.0 mg + V-CB 0.0 mg, (c) IN-NLX 0.0 mg + V-CB 12.5 mg, (d) IN-NLX 4.0 mg + V-CB 12.5 mg, (e) IN-NLX 0.0 mg + V-CB 0.0 mg, and (f) IN-NLX 4.0 mg + V-CB 25.0 mg. Naloxone alone resulted in a COWS score of 22 at T+30. CB pretreatment (12.5 mg and 25.0 mg) reduced COWS scores at T+30 to 17 and 14, respectively. Active NLX and V-CB administered in combination resulted in elevated heart rate and blood pressure, though not to a greater extent than NLX alone. This study found that the addition of a cannabinoid reduced the severity of NLX-precipitated withdrawal and supported the continued investigation into combined NLX + cannabinoid formulations as overdose reversal agents. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
- Open Access
- 15 October 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (1)
Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids
Introduction: The global drug market has seen an emergence of potent synthetic opioids, including benzimidazole‐derived substances known as nitazenes. These compounds have been implicated in fatal and non‐fatal overdoses. This review aims to synthesise current evidence on the pharmacological effects, potency and naloxone responsiveness of new synthetic opioids, with a focus on synthetic opioids evaluated for international control since 2020. It highlights key findings that can inform our understanding of these substances and inform harm reduction strategies. Methods: A narrative review was conducted using critical reviews from the World Health Organization Expert Committee on Drug Dependence and supplementary literature. Data extraction focused on pharmacological profiles, behavioural effects, potency estimates, and naloxone effectiveness. Results: Thirteen synthetic opioids were examined, with potencies ranging from similar to morphine to exceeding that of fentanyl. Naloxone demonstrated efficacy in reversing overdose symptoms for most substances, although higher doses or infusions were occasionally required. Discussion and Conclusions: The variability in nitazene potency and common unintended use underscores the need for widespread education, broad naloxone access and robust drug‐checking initiatives. Key challenges include the detection of nitazenes in polydrug contexts and their presence in substances sold as other drugs, including falsified pharmaceuticals. Emerging evidence suggests that naloxone can reverse acute poisonings with benzimidazole opioids. However, no studies have examined the effectiveness of medications for treating opioid use disorder (e.g., methadone, buprenorphine, naltrexone) in people who are physically dependent on nitazenes. Future research should address this important knowledge gap.
- 15 October 2025
- Published by Wiley in Drug and Alcohol Review
- Vol. 45 (1)
Open AccessBehavioural Effects and Naloxone Effectiveness With New Synthetic Opioids
Introduction: The global drug market has seen an emergence of potent synthetic opioids, including benzimidazole‐derived substances known as nitazenes. These compounds have been implicated in fatal and non‐fatal overdoses. This review aims to synthesise current evidence on the pharmacological effects, potency and naloxone responsiveness of new synthetic opioids, with a focus on synthetic opioids evaluated for international control since 2020. It highlights key findings that can inform our understanding of these substances and inform harm reduction strategies. Methods: A narrative review was conducted using critical reviews from the World Health Organization Expert Committee on Drug Dependence and supplementary literature. Data extraction focused on pharmacological profiles, behavioural effects, potency estimates, and naloxone effectiveness. Results: Thirteen synthetic opioids were examined, with potencies ranging from similar to morphine to exceeding that of fentanyl. Naloxone demonstrated efficacy in reversing overdose symptoms for most substances, although higher doses or infusions were occasionally required. Discussion and Conclusions: The variability in nitazene potency and common unintended use underscores the need for widespread education, broad naloxone access and robust drug‐checking initiatives. Key challenges include the detection of nitazenes in polydrug contexts and their presence in substances sold as other drugs, including falsified pharmaceuticals. Emerging evidence suggests that naloxone can reverse acute poisonings with benzimidazole opioids. However, no studies have examined the effectiveness of medications for treating opioid use disorder (e.g., methadone, buprenorphine, naltrexone) in people who are physically dependent on nitazenes. Future research should address this important knowledge gap.
- 24 June 2024
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 262, 111375
Empirical assessment of wounds among people who use substances
- 24 June 2024
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 262, 111375
Empirical assessment of wounds among people who use substances
- 24 April 2024
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 240, 173771
The influence of drug class on reward in substance use disorders
- 24 April 2024
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 240, 173771
The influence of drug class on reward in substance use disorders
- 3 November 2023
- Published by Wiley in Drug and Alcohol Review
- Vol. 43 (1) , 343-346
Opioid overdose knowledge among college students compared to experienced opioid users
- 3 November 2023
- Published by Wiley in Drug and Alcohol Review
- Vol. 43 (1) , 343-346
Opioid overdose knowledge among college students compared to experienced opioid users
- 26 September 2023
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 59 (1) , 41-49
Resilience Phenotypes and Psychological Functioning among Individuals with Opioid Use Disorder
Opioid use disorder (OUD) is a heterogeneous disorder. However, there is a lack of deep phenotyping investigations focusing on important psychological constructs such as resilience that may impact OUD. The present study aimed to investigate the relationship between trait resilience and the five-factor model of personality (FFM) among individuals with opioid use disorder (OUD). We also explored whether the FFM and trait resilience form specific phenotypes associated with psychological functioning. This secondary analysis of an epigenetic study included participants of African ancestry (n = 72), an understudied population, who met DSM-5 criteria for OUD. Participants completed measures to assess personality traits, trait resilience, current and previous drug use, and psychological functioning (depression, anxiety, and stress). Linear regression revealed a significant relationship between resilience (CD-RISC-25 score) and the FFM, R2 = 0.56, F(5,62) = 15.7, p<.001. Further, a two-cluster classification emerged as the optimal solution from the cluster analysis. Cluster 1 (n = 33, 45.8% of the sample) showed lower resilience (CD-RISC-25 score: M = 58.6, SD = 11.2) compared to Cluster 2 (n = 35, 48.6%; CD-RISC-25 score: M = 76.1, SD = 11.9). The "High-Resilience Cluster" (Cluster 2) was characterized by higher FFM traits of: Extraversion, Openness, Agreeableness, and Conscientiousness, and lower Neuroticism versus Cluster 1. Multivariate analysis of variance revealed statistically significant differences between the two resilience clusters concerning other psychological symptoms, Λ = 0.732, F(4, 50) = 7.05, p < 0.003. These findings suggest associations between the FFM and trait resilience among individuals with OUD. Two distinct "resilience phenotypes" emerged, with high-resilience individuals displaying less stress, anxiety, and depressive symptoms. Results highlight the clinical importance of resilience as a potential target for intervention in people with OUD.
- 26 September 2023
- Published by Taylor & Francis in Substance Use & Misuse
- Vol. 59 (1) , 41-49
Resilience Phenotypes and Psychological Functioning among Individuals with Opioid Use Disorder
Opioid use disorder (OUD) is a heterogeneous disorder. However, there is a lack of deep phenotyping investigations focusing on important psychological constructs such as resilience that may impact OUD. The present study aimed to investigate the relationship between trait resilience and the five-factor model of personality (FFM) among individuals with opioid use disorder (OUD). We also explored whether the FFM and trait resilience form specific phenotypes associated with psychological functioning. This secondary analysis of an epigenetic study included participants of African ancestry (n = 72), an understudied population, who met DSM-5 criteria for OUD. Participants completed measures to assess personality traits, trait resilience, current and previous drug use, and psychological functioning (depression, anxiety, and stress). Linear regression revealed a significant relationship between resilience (CD-RISC-25 score) and the FFM, R2 = 0.56, F(5,62) = 15.7, p<.001. Further, a two-cluster classification emerged as the optimal solution from the cluster analysis. Cluster 1 (n = 33, 45.8% of the sample) showed lower resilience (CD-RISC-25 score: M = 58.6, SD = 11.2) compared to Cluster 2 (n = 35, 48.6%; CD-RISC-25 score: M = 76.1, SD = 11.9). The "High-Resilience Cluster" (Cluster 2) was characterized by higher FFM traits of: Extraversion, Openness, Agreeableness, and Conscientiousness, and lower Neuroticism versus Cluster 1. Multivariate analysis of variance revealed statistically significant differences between the two resilience clusters concerning other psychological symptoms, Λ = 0.732, F(4, 50) = 7.05, p < 0.003. These findings suggest associations between the FFM and trait resilience among individuals with OUD. Two distinct "resilience phenotypes" emerged, with high-resilience individuals displaying less stress, anxiety, and depressive symptoms. Results highlight the clinical importance of resilience as a potential target for intervention in people with OUD.
- Open Access
- 18 April 2023
- Published by Elsevier in Addiction Neuroscience
- Vol. 7
No evidence of accelerated epigenetic aging among black heroin users: A case vs control analysis
- 18 April 2023
- Published by Elsevier in Addiction Neuroscience
- Vol. 7
Open AccessNo evidence of accelerated epigenetic aging among black heroin users: A case vs control analysis
- 2 January 2023
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 32 (1) , 77-87
Immunotherapeutic strategies for treating opioid use disorder and overdose
Development and implementation of effective treatments for opioid use disorder (OUD) and prevention of overdose are urgent public health needs. Though existing medications for OUD (MOUD) are effect...
- 2 January 2023
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 32 (1) , 77-87
Immunotherapeutic strategies for treating opioid use disorder and overdose
Development and implementation of effective treatments for opioid use disorder (OUD) and prevention of overdose are urgent public health needs. Though existing medications for OUD (MOUD) are effect...
- 2 January 2023
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 49 (1) , 109-122
Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial
Background: Like other alpha-2-adrenergic receptor agonists, dexmedetomidine may reduce the severity of opioid withdrawal but with fewer adverse cardiovascular effects. Objective: This study assessed the safety of sublingual dexmedetomidine (BXCL501) and its preliminary efficacy in treating opioid withdrawal (ClinicalTrials.gov: NCT04470050). Methods: Withdrawal was induced among individuals with physiological dependence on opioids via discontinuation of oral morphine (Days 1–5). Participants were randomized to receive placebo or active BXCL501: 30, 60, 90, 120, 180, and 240 μg twice daily (Days 6–12). Treatment-emergent adverse events (TEAEs) were the primary outcome measure. Secondary outcomes included the Clinical and Subjective Opiate Withdrawal Scales (COWS and SOWS-Gossop, respectively), and the Agitation and Calmness Evaluation Scale (ACES). Results: Of 225 participants enrolled, 90 discontinued during morphine stabilization. Post-BXCL501 randomization (Day 6) data were available from 135 participants (73% male), with 33% completing thru Day 12. In total, 36 subjects reported 1 or more TEAE. Higher doses of BXCL501 (i.e. 180 and 240 µg, twice daily) increased the frequency of: hypotension, orthostatic hypotension, and somnolence. TEAEs related to BXCL501 were mild or moderate in severity, except for one participant in the 120 µg condition whose orthostatic hypotension and bradycardia were classified as severe. Higher BXCL501 dose conditions (120, 180, and 240 µg) resulted in statistically significant reductions in COWS & SOWS scores. Mean ratings on the ACES were between 3 (mild), 4 (normal), and 5 (mild calmness), with few significant differences as a function of dose. Conclusions: These findings support the continued development of BXCL501 for the management of opioid withdrawal.
- 2 January 2023
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 49 (1) , 109-122
Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial
Background: Like other alpha-2-adrenergic receptor agonists, dexmedetomidine may reduce the severity of opioid withdrawal but with fewer adverse cardiovascular effects. Objective: This study assessed the safety of sublingual dexmedetomidine (BXCL501) and its preliminary efficacy in treating opioid withdrawal (ClinicalTrials.gov: NCT04470050). Methods: Withdrawal was induced among individuals with physiological dependence on opioids via discontinuation of oral morphine (Days 1–5). Participants were randomized to receive placebo or active BXCL501: 30, 60, 90, 120, 180, and 240 μg twice daily (Days 6–12). Treatment-emergent adverse events (TEAEs) were the primary outcome measure. Secondary outcomes included the Clinical and Subjective Opiate Withdrawal Scales (COWS and SOWS-Gossop, respectively), and the Agitation and Calmness Evaluation Scale (ACES). Results: Of 225 participants enrolled, 90 discontinued during morphine stabilization. Post-BXCL501 randomization (Day 6) data were available from 135 participants (73% male), with 33% completing thru Day 12. In total, 36 subjects reported 1 or more TEAE. Higher doses of BXCL501 (i.e. 180 and 240 µg, twice daily) increased the frequency of: hypotension, orthostatic hypotension, and somnolence. TEAEs related to BXCL501 were mild or moderate in severity, except for one participant in the 120 µg condition whose orthostatic hypotension and bradycardia were classified as severe. Higher BXCL501 dose conditions (120, 180, and 240 µg) resulted in statistically significant reductions in COWS & SOWS scores. Mean ratings on the ACES were between 3 (mild), 4 (normal), and 5 (mild calmness), with few significant differences as a function of dose. Conclusions: These findings support the continued development of BXCL501 for the management of opioid withdrawal.
Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance
Background and Aims: Fentanyl is a highly lipophilic mu opioid receptor agonist, increasingly found in heroin and other drug supplies, that is contributing to marked increases in opioid‐related overdose and may be complicating treatment of opioid use disorder (OUD). This study aimed to measure the influence of body mass index (BMI) on fentanyl withdrawal and clearance.Design, Setting, Participants: This secondary analysis, from a 10‐day inpatient study on the safety and efficacy of sublingual dexmedetomidine for opioid withdrawal, includes participants with OUD (n = 150) recruited from three sites in New York, New Jersey and Florida, who were maintained on oral morphine (30 mg four times per day) for 5 days before starting study medication. Most participants (n = 118) tested positive for fentanyl on admission to the inpatient unit.Measurements: Urine toxicology and opioid withdrawal symptoms [Clinical Opioid Withdrawal Scale (COWS) and Short Opiate Withdrawal Scale (SOWS)] were assessed daily. The present analysis includes data on opioid withdrawal from days 1–5 of stabilization and urine toxicology data from days 1–10.Findings: Fentanyl status at admission was not significantly associated with COWS or SOWS scores after adjusting for sex, site and polysubstance use. Participants classified as overweight or obese (n = 66) had significantly higher odds of testing positive for fentanyl across days 1–10 [odds ratio (OR) = 1.65; P < 0.01] and higher SOWS maximum scores across morphine stabilization (P < 0.05) compared to those with a healthy BMI (n = 68).Conclusions: Among inpatients with opioid use disorder, fentanyl status does not appear to be statistically significantly associated with Clinical Opioid Withdrawal Scale and Short Opiate Withdrawal Scale mean and maximum scores. High body mass index status (overweight or obese) appears to be an important predictor of slower fentanyl clearance and higher Short Opiate Withdrawal Scale maximum scores across the inpatient period than lower body mass index status.
Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance
Background and Aims: Fentanyl is a highly lipophilic mu opioid receptor agonist, increasingly found in heroin and other drug supplies, that is contributing to marked increases in opioid‐related overdose and may be complicating treatment of opioid use disorder (OUD). This study aimed to measure the influence of body mass index (BMI) on fentanyl withdrawal and clearance.Design, Setting, Participants: This secondary analysis, from a 10‐day inpatient study on the safety and efficacy of sublingual dexmedetomidine for opioid withdrawal, includes participants with OUD (n = 150) recruited from three sites in New York, New Jersey and Florida, who were maintained on oral morphine (30 mg four times per day) for 5 days before starting study medication. Most participants (n = 118) tested positive for fentanyl on admission to the inpatient unit.Measurements: Urine toxicology and opioid withdrawal symptoms [Clinical Opioid Withdrawal Scale (COWS) and Short Opiate Withdrawal Scale (SOWS)] were assessed daily. The present analysis includes data on opioid withdrawal from days 1–5 of stabilization and urine toxicology data from days 1–10.Findings: Fentanyl status at admission was not significantly associated with COWS or SOWS scores after adjusting for sex, site and polysubstance use. Participants classified as overweight or obese (n = 66) had significantly higher odds of testing positive for fentanyl across days 1–10 [odds ratio (OR) = 1.65; P < 0.01] and higher SOWS maximum scores across morphine stabilization (P < 0.05) compared to those with a healthy BMI (n = 68).Conclusions: Among inpatients with opioid use disorder, fentanyl status does not appear to be statistically significantly associated with Clinical Opioid Withdrawal Scale and Short Opiate Withdrawal Scale mean and maximum scores. High body mass index status (overweight or obese) appears to be an important predictor of slower fentanyl clearance and higher Short Opiate Withdrawal Scale maximum scores across the inpatient period than lower body mass index status.